Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.76+1.93 (+68.20%)
Close on Nov 18, 2026Market cap $34.58MP/E –Yield –
Cue Biopharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Cue Biopharma's free cash flow for the twelve months ending Jun 30, 2026 was -$50.17M. For fiscal 2025 it was -$21.86M. The highest annual figure on record is -$13.17M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$21.86M | – |
| FY2024 | Dec 31, 2024 | -$36.40M | – |
| FY2023 | Dec 31, 2023 | -$39.96M | – |
| FY2022 | Dec 31, 2022 | -$41.98M | – |
| FY2021 | Dec 31, 2021 | -$39.75M | – |
| FY2020 | Dec 31, 2020 | -$33.09M | – |
| FY2019 | Dec 31, 2019 | -$30.84M | – |
| FY2018 | Dec 31, 2018 | -$28.27M | – |
| FY2017 | Dec 31, 2017 | -$13.17M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$29.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.06M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.44M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.32M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.53M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.00M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.84M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.83M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.52M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.91M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.60M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.64M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.02M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.44M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.11M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.45M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.23M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.68M | – |
| Q1 FY2019 | Mar 31, 2019 | -$8.49M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.02M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.60M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.22M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.43M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.86M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.88M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.40M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.02M | – |
See a number that looks wrong?